Medication Pearl of the Day: Vedolizumab (Entyvio)
Indication: Vedolizumab (Entyvio) is an integrin receptor antagonist indicated for adult patients with moderately to severely active ulcerative colitis (UC) and adult patients with moderately to severely active Crohn disease (CD).
- Dosing:Recommended dosage in UC and CD 300 mg infused intravenously over approximately 30 minutes at zero, 2 and 6 weeks, then every 8 weeks thereafter.
- Dosage forms: For injection 300 mg of lyophilized vedolizumab in a single-use 20 mL vial.
- Adverse events:Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.
- Mechanism of action: Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule-1 (VCAM-1).
- Manufacturer: Takeda Pharmaceuticals